A bill to improve the inspections of drug establishments engaged in the manufacture, preparation, propagation, or processing of biosimilar biological products conducted by the Food and Drug Administration, and for other purposes.

Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Sent to a congressional committee for expert review. The committee decides whether this bill moves forward.

Introduced in Senate

The bill was officially filed and given a number. It now enters the legislative queue.